Cargando…
Mechanism of sorafenib resistance associated with ferroptosis in HCC
Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor prognosis. The incidence of HCC and the associated deaths have risen in recent decades. Sorafenib is the first drug to be approved by the Food and Drug Administration (FDA) for routine use in the first-line th...
Autores principales: | Guo, Lingling, Hu, Cuntao, Yao, Mengwen, Han, Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282186/ https://www.ncbi.nlm.nih.gov/pubmed/37351514 http://dx.doi.org/10.3389/fphar.2023.1207496 |
Ejemplares similares
-
Ferroptosis: a new regulatory mechanism in neuropathic pain
por: Li, Lu, et al.
Publicado: (2023) -
Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020) -
Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management
por: Lin, Yan, et al.
Publicado: (2022) -
ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression
por: Li, Yilan, et al.
Publicado: (2022) -
TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)